FDA adcomm raises questions on effectiveness of Grail's cancer test
Members of the FDA's Molecular and Clinical Genetics Panel and FDA officials on Wednesday raised questions about Grail's next-generation sequencing test for the early detection of multiple types of cancer in adults over 50. The ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.